Aptose Biosciences Inc. Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Note 3 - Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Consolidated Statements of Financial Position	December 31, 2016						January 1, 2016
	Canadian dollars			US dollars			Canadian dollars			US dollars
Assets
Current assets:
Cash and cash equivalents	$	10,662		$	7,940		$	11,503		$	8,311
Investments		-			-			8,245			5,957
Prepaid expenses and other assets		663			493			1,067			771
Total current assets		11,325			8,433			20,815			15,039

Non-current assets:
Equipment and intangibles		285			213			434			314
Total non-current assets		285						434			314
Total assets	$	11,610			8,646		$	21,249		$	15,353

Liabilities and Shareholder’s Equity
Current liabilities:
Accounts payable and accrued liabilities	$	1,770		$	1,318		$	2,356		$	1,702
Total current liabilities		1,770			1,318			2,356			1,702

Shareholders’ equity:
Share capital :
Common shares		230,976			218,034			223,425			212,308
Stock options		8,133			7,306			6,256			5,740
Contributed surplus		22,267			21,413			22,037			21,188
Warrants		-			-			84			85
Accumulated other comprehensive income		-			(4,298	)		-			(4,783	)
Deficit		(251,536	)		(235,127	)		(232,909	)		(220,887	)
Total shareholders’ equity		9,840			7,328			18,893			13,651

Total liabilities and shareholders’ equity	$	11,610		$	8,646		$	21,249		$	15,353

	Year ended December 31, 2016						Year ended December 31, 2015
	Canadian dollars			US dollars			Canadian dollars			US dollars

Revenue	$	-		$	-			-		$	-

Expenses:
Research and development		10,322			7,834			6,254			4,865
General and administrative		8,344			6,439			9,845			7,992
		18,666			14,273			16,099			12,857
Finance expense		66			46			43			34
Finance income		(105	)		(79	)		(1,516	)		(1,180	)
Net finance (income) expense		(39	)		(33	)		(1,473	)		(1,146	)
Net loss for the year	$	(18,627	)		(14,240	)		(14,626	)	$	(11,711	)

Other comprehensive loss
Items that may subsequently be reclassified to earnings
Foreign currency translation gain (loss)		-			485			-			(3,519	)
Comprehensive loss for the year	$	(18,627	)	$	(13,755	)		(14,626	)	$	(15,230	)

Basic and diluted loss per common share	$	(1.46	)		(1.12	)		(1.23	)	$	(0.98	)